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Correction
Following publication of our recent article [1], an error in 
Figure 5d was noticed. In Figure 5d, the β-actin blot 
corres  ponding to α-SMA blot was captured on the 
chemi  luminescence imaging system in an inverted orien-
tation. Since this imager does not capture the protein 
marker, an error in the orientation of the membrane 
while capturing the picture of the blot occurred. During 
preparation of the ﬁ  gures for Figure 5d, the α-SMA blot 
was in right orientation but since orientation of β-actin 
blot was inverse as it was captured inversely resulted in 
non-corresponding β-actin blot with respect to α-SMA 
blot. We have rectiﬁ  ed this error now and β-actin blot 
now corresponds to α-SMA blot. Th   e corrected ﬁ  gure 5 
is given here as Figure 1 and a supplementary ﬁ  gure 1 
(Additional ﬁ  le 1) showing another set of blots repre-
senting Figure 5d is also provided.
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Additional fi  le 1
Supplementary Figure 1. mPGES-1 genetic deletion results in 
reduced α-SMA expression in response to bleomycin treatment.
Description. Protein extracts from skin tissue after 4 weeks of 
bleomycin or PBS treatment were subjected to Western blot 
analysis with an anti-α-SMA antibody. mPGES-1 null mice treated 
with bleomycin showed reduced α-SMA expression compared with 
bleomycin-treated WT mice. Representative blot from four separate 
animals/group/genotype is shown. (b) Graph represents α-SMA 
expression normalized to β-actin expression from four separate 
animals/group/genotype. *P < 0.05; bleomycin-treated WT and 
mPGES-1 null mice compared with PBS-treated mice. +P < 0.05; 
bleomycin-treated mPGES-1 null mice compared with bleomycin-
treated WT mice. α-SMA, alpha-smooth muscle actin; β-actin, beta-
actin; mPGES-1, microsomal prostaglandin E2 synthase-1.
Format. JPG. Download fi  le at: http://arthritis-research.com/content/
supplementary/ar3285-s1.jpg
McCann et al. Arthritis Research & Therapy 2011, 13:402 
http://arthritis-research.com/content/13/2/402
© 2011 BioMed Central LtdFigure 1. mPGES-1 genetic deletion results in reduced collagen content and myofi  broblast formation in vivo. (a) Hydroxyproline analysis 
showed reduced collagen content in mPGES-1 null mice compared with wild-type (WT) mice in response to bleomycin treatment. Data from 
four separate mice per group are shown. (b, c) Immunohistochemistry using anti-α-SMA antibody was performed. mPGES-1 null mice showed 
a reduced number of α-SMA-expressing myofi  broblasts compared with WT mice in response to bleomycin treatment (4-week treatment). 
Representative data from four separate animals per group are shown. *P < 0.05; bleomycin-treated WT and mPGES-1 null mice compared 
with phosphate-buff  ered saline (PBS)-treated mice. +P < 0.05; bleomycin-treated mPGES-1 null mice compared with bleomycin-treated WT 
mice. (d) Protein extracts from skin tissue after 4 weeks of bleomycin or PBS treatment were subjected to Western blot analysis with an anti-
α-SMA antibody. mPGES-1 null mice treated with bleomycin showed reduced α-SMA expression compared with bleomycin-treated WT mice. 
Representative blot from four separate animals per group is shown. α-SMA, alpha-smooth muscle actin; mPGES-1, microsomal prostaglandin E2 
synthase-1.
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